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EbolaEbola (EBOV) and Marburg virus (MARV) cause severe hemorrhagic fever. The host cell proteases cathepsin B
and L activate the Zaire ebolavirus glycoprotein (GP) for cellular entry and constitute potential targets for
antiviral intervention. However, it is unclear if different EBOV species and MARV equally depend on cathepsin
B/L activity for infection of cell lines and macrophages, important viral target cells. Here, we show that ca-
thepsin B/L inhibitors markedly reduce 293T cell infection driven by the GPs of all EBOV species, independent
of the type II transmembrane serine protease TMPRSS2, which cleaved but failed to activate EBOV-GPs. Sim-
ilarly, a cathepsin B/L inhibitor blocked macrophage infection mediated by different EBOV-GPs. In contrast,
MARV-GP-driven entry exhibited little dependence on cathepsin B/L activity. Still, MARV-GP-mediated
entry was efﬁciently blocked by leupeptin. These results suggest that cathepsins B/L promote entry of
EBOV while MARV might employ so far unidentiﬁed proteases for GP activation.
© 2011 Elsevier Inc. All rights reserved.Introduction
Ebola virus (EBOV) and Marburg virus (MARV), negative strand
RNA viruses of the ﬁloviridae family, can cause severe hemorrhagic
fever in humans. A single species of MARV, Lake Victoria marburgvirus,
has been identiﬁed (Hartman et al., 2010), while EBOVs are separated
into four species, Zaire ebolavirus (ZEBOV), Sudan ebolavirus (SEBOV),
Cote d'Ivoire ebolavirus (CIEBOV) and Reston ebolavirus (REBOV)
(Feldmann and Geisbert, 2011; Hartman et al., 2010). A ﬁfth species,
Bundibugyo ebolavirus (BEBOV), has been proposed (Towner et al.,
2008). Outbreaks of ZEBOV, SEBOV, CIEBOV, BEBOV and MARV
occur sporadically in Africa and are associated with case-fatality
rates of up to 90%. In contrast, REBOV has been detected in pigs in
the Philippines and seems to be apathogenic in humans (Feldmann
and Geisbert, 2011; Hartman et al., 2010).
EBOV and MARV bear a single glycoprotein (GP) in their envelope
which mediates infectious viral entry into host cells and constitutes an
important target for prevention and therapy. Many glycoproteins relat-
ed to the EBOV-GP, like theHIV envelope protein (Env), are synthesized
as inactive precursor proteins in the constitutive secretory pathway of
infected cells and require activation by host cell proteases to transit
into an active form (Bertram et al., 2010b). Both EBOV-GP and HIV
Env are cleaved by furin in the Golgi apparatus of infected cellsection Biology Unit, Kellnerweg
.
rights reserved.(Hallenberger et al., 1992; Volchkov et al., 1998) and cleavage at the
furin consensus site is essential for HIV infectivity (McCune et al.,
1988). In contrast, GP cleavage by furin is dispensable for EBOV spread
in cell culture and in animals (Neumann et al., 2002, 2007; Wool-Lewis
and Bates, 1999), indicating that furin does not activate GP. Work by
Chandran et al. (2005) and subsequent studies (Kaletsky et al., 2007;
Schornberg et al., 2006) suggest that ZEBOV-GP is activated by the
pH-dependent cysteine proteases cathepsin B and L (termed cathepsins
B/L in the remainder of the manuscript) upon viral entry into host cell
endosomes. In addition, a link between α5β1 integrin expression, ca-
thepsin B/L activity and GP-mediated entry has been revealed
(Schornberg et al., 2009), in line with a previous report indicating that
β1 integrins promote EBOV-GP-dependent host cell entry (Takada et
al., 2000). However, it is at present unclear if all EBOV species and
MARV are comparably dependent on cathepsin B/L activity for viral
entry and it is unknown if cathepsin B/L activity is required for GP-
driven entry into macrophages, central target cells of ﬁloviruses.
The cell entry of the severe acute respiratory syndrome coronavi-
rus (SARS-CoV) also requires activation of the viral envelope protein
spike (S) by cathepsins B and L (Simmons et al., 2005). However, ex-
pression of the type II transmembrane serine protease (TTSP)
TMPRSS2, a cell-associated protease known to activate inﬂuenza
virus (Böttcher et al., 2006; Chaipan et al., 2009) and human metap-
neumovirus (Shirogane et al., 2008), allows cathepsin B/L-indepen-
dent host cell entry, indicating that SARS-CoV can use different
proteases to ensure activation of its S-protein (Glowacka et al.,
2011; Matsuyama et al., 2010; Shulla et al., 2011). These ﬁndings
Fig. 1. Inhibition of cathepsin B, L and S activity by protease inhibitors. 293T cells were
incubated with the indicated inhibitors and cathepsin activity was determined 8 h later
using commercially available kits. The cathepsin B, L and S activity in cells treated with
protease inhibitors is shown relative to that measured upon treatment of cells with
PBS, which was set as 100%. Results for cathepsin B and L activity represent the average
of three independent experiments. Error bars indicate standard error of the mean. The
results of a representative experiment performed in duplicates are shown for cathepsin
S and were conﬁrmed in a separate experiment. Error bars indicate standard deviation
(SD). CatB, cathepsin B; CatL, cathepsin L; CatS, cathepsin S.
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cytes, major viral target cells (Glowacka et al., 2011; Matsuyama et
al., 2010), suggest that inhibition of cathepsin B/L activity might not
appreciably reduce viral spread in infected patients. Whether TTSPs
can also cleave and activate EBOV-GP for cathepsin B/L-independent
host cell entry is unknown.
Here, we show that dependence on cathepsin B/L-activity for entry
into 293T cells is conserved between the GPs of the four EBOV species
and is not modulated by expression of TMPRSS2. Macrophage infection
driven by different EBOV-GPswas also dependent on cathepsin B/L activ-
ity, in linewith theﬁndingsmadewith 293T cells. In contrast,MARV-GP-
mediated infection exhibited little dependence on cathepsin B/L activity,
indicating thatMARV-GP can use other proteases to ensure its activation.
Results
Inhibition of cathepsin B and L activity by protease inhibitors
In order to assess the proteolytic activation of EBOV-GP by cathepsins
B and L, we selected a panel of previously characterized, commercially
available inhibitors (Table 1). For several of these inhibitors, we deter-
mined their activity against cathepsins B, L and S in 293T cells, employing
inhibitor concentrations subsequently used for infection experiments.
CA074, a cathepsin B inhibitor (Sigma), potently blocked cathepsin B ac-
tivity, as expected, but at a concentration of 100 μMalso reduced cathep-
sin L activity by about 70% (Fig. 1). CA074Me, a CA074 derivative with
high membrane permeability (Calbiochem), exhibited activity similar
to CA074 at the concentrations tested. Notably, CA074Mewas previously
shown to inhibit cellular entry of ecotropicmurine leukemia virus via in-
hibition of cathepsin L, demonstrating that the modest activity of
CA074Me against cathepsin L (Fig. 1) can be sufﬁcient to exert antiviral
effects (Yoshii et al., 2009). Cathepsin L inhibitor III, an irreversible inhib-
itor of cathepsin L (Merck), was highly active against cathepsin L but,
unexpectedly, also inhibited cathepsin B with similar efﬁciency (Fig. 1).
AEBSF, a serine protease inhibitor (Roth), displayed no activity against
cathepsins B and L. E64c, a cysteine protease inhibitor (Sigma), fully
inhibited cathepsin B and reduced cathepsin L activity by half when ap-
plied at a concentration of 50 μM (Fig. 1). None of the inhibitors tested
were active against cathepsin S, indicating a substantial level of selectiv-
ity, although inhibition of other cysteine cathepsins, like cathepsins H, K
and O, has not been tested. Finally, leupeptin, a well characterized inhib-
itor of serine and cysteine proteases (Aoyagi et al., 1969), and MDL
28170, an efﬁcient inhibitor of cathepsin B activity (Mehdi, 1991), ca-
thepsin L activity (Simmons et al., 2005) and SARS-S driven host cell
entry (Simmons et al., 2005), were also included in the panel.
The glycoproteins of all Ebola virus species depend on cathepsin B and L
activity for host cell entry
Cathepsins B and L were previously shown to activate ZEBOV-GP
for host cell entry (Chandran et al., 2005). In order to address if theTable 1
Speciﬁcity and commercial source of protease inhibitors used in the present study.
Inhibitor Distributor Protease speciﬁcity⁎ CatL CatB CatS
Leupeptin Sigma Cysteine-, serine-
proteases
n.d. n.d. n.d.
AEBSF Roth Serine-proteases − − −
E64c Sigma Cysteine proteases (+) ++ −
MDL28170 Sigma Calpain I and II n.d. n.d. n.d.
CA074 Sigma Cathepsin B (+) ++ −
CA074Me Calbiochem Cathepsin B (+) ++ −
Cathepsin L inhibitor III Merck Cathepsin L + (+) −
⁎According to distributor, ++ = more than 100-fold inhibition at highest concentra-
tion tested, + = 10–100 fold inhibition at highest concentration tested, (+) = 2–10
fold inhibition at highest concentration tested, −= no inhibition, n.d., not done.GPs of different EBOVs are activated differentially by host cell prote-
ases, we compared activation of GP derived from ZEBOV and REBOV,
which exhibit differential pathogenicity in humans (Feldmann and
Geisbert, 2011). For this, we employed infectivity-normalized HIV-
derived vectors pseudotyped with ZEBOV- and REBOV-GP for infec-
tion of 293T target cells that were either pretreated with protease in-
hibitor (Fig. 2, gray and black bars) or inhibitor solvent as control
(white bars). Particles bearing no GP (Fig. 2, pcDNA3) or the
G-protein of vesicular stomatitis virus (VSV-G) were used as controls.
AEBSF treatment of target cells had no effect on entry of all
pseudotypes tested (Fig. 2A, upper panel, right), while leupeptin
inhibited ZEBOV- and REBOV-GP-dependent entry (Fig. 2A, upper
panel, left), indicating that cysteine but not serine proteases are in-
volved in EBOV-GP activation. MDL28170 and E64c both inhibited
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Fig. 2. Entry driven by the glycoproteins of the four Ebola virus species depends on cathepsin activity. A. 293T target cells were preincubated with the indicated concentrations of
cathepsin B and L inhibitors (MDL28170, E64c), a serine protease inhibitor (AEBSF) and an inhibitor blocking cysteine and serine proteases (leupeptin). Subsequently, cells were
infected with pseudotypes bearing the indicated GPs, normalized for equal infectivity. Luciferase activity in cell lysates was measured at 72 h post infection. B. The experiment was
carried out as described in (A), using two different concentrations of cathepsin L inhibitor III and cathepsin B inhibitor CA074. C. The experiment was carried out as described in
(A) but cells were incubated with the cathepsin B inhibitor CA074Me. The results of representative experiments performed in triplicates are shown in A–C; error bars indicate
SD. Similar results were obtained in three separate experiments.
5K. Gnirß et al. / Virology 424 (2012) 3–10ZEBOV- and REBOV-GP-driven entry, in agreement with the concept
that cathepsins B/L can activate EBOV-GP (Fig. 2A, lower panel). How-
ever, the relative importance of cathepsins B and L for activation of
these glycoproteins might differ, since cathepsin L inhibitor III
(Table 1), which displayed the highest activity against cathepsin Lof all compounds tested, inhibited cell entry driven by both ZEBOV-
and REBOV-GP, while the largely cathepsin B-speciﬁc inhibitor
CA074 (Table 1) was active only against ZEBOV-GP (Fig. 2B). Finally,
CA074Me, which reduced cathepsin B activity by about 99.9% and ca-
thepsin L activity by about 70% at a concentration of 4 μM (Fig. 1),
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different efﬁciencies (Fig. 2C), suggesting that cathepsin B and poten-
tially also cathepsin L dependence for host cell entry is conserved be-
tween EBOV-GPs. In sum, these results indicate that efﬁcient cellular
entry driven by the GPs of the EBOV species depends on the activity
of cathepsins B and/or L, while the relative contribution of both en-
zymes to GP activation might vary between the EBOV species.
Evidence that the Marburg virus glycoprotein can be activated by prote-
ases other than cathepsins B and L
A previous study indicated that replication competent MARV might
not depend on cathepsin B/L activity for host cell entry (Sanchez, 2007).
Cellular entry of lentiviral vectors pseudotyped with MARV-GP showed
variable dependence on cathepsin B and L activity: CA074Me, when ap-
plied at a concentration of 4 μM,modestly suppressedMARV-GP-driven
entry into 293T cells (3.3- to 6.2-fold inhibition, data not shown) in two
experiments but had no appreciable effect in two separate experiments
(0- to 1.5-fold inhibition, Fig. 3 and data not shown). These results sug-
gest that MARV-GP is indeed less dependent on cathepsin B/L activity
for entry into 293T cellswhen compared to EBOV-GP. However, leupep-
tin but not AEBSF robustly and invariably suppressed host cell entry
driven by MARV-GP (Fig. 3), demonstrating that MARV-GP like EBOV-
GP depends on activation by host cell proteases for infectious entry,
and the nature of the responsible protease(s) remains to be deﬁned.
Type II transmembrane serine proteases cannot substitute for cathepsins
B/L in Ebolavirus glycoprotein-driven host cell entry
The S-protein of SARS-CoV is also activated by cathepsins B and L
(Simmons et al., 2005). However, the dependence on cathepsin activ-
ity is markedly reduced if target cells express the type II transmem-
brane serine protease TMPRSS2 (Glowacka et al., 2011; Matsuyama
et al., 2010; Shulla et al., 2011). We next addressed if TMPRSS2 and
the related protease hepsin modulate cathepsin-dependence of
EBOV-GP for host cell entry. For this, we coexpressed EBOV-GPs
with a C-terminal V5 tag and TMPRSS2 or hepsin in 293T cells and an-
alyzed GP cleavage by Western blot. All GPs were cleaved in the ab-
sence of TTSP expression (Fig. 4), in agreement with the previously
published ﬁnding that GP is proteolytically processed by furin
(Volchkov et al., 1998), an ubiquitously expressed pre-protein con-
vertase active in the 293T cell line used for GP expression in the pre-
sent study (Bush et al., 2001; Yano et al., 2009). However, cleavage
efﬁciency differed between the GPs analyzed: ZEBOV- and SEBOV-
GP were efﬁciently cleaved while cleavage of CIEBOV- and REBOV-
GP was inefﬁcient (Fig. 4). Notably, the inefﬁcient cleavage of
REBOV-GP was rescued by hepsin coexpression, and TMPRSS2 coex-
pression allowed efﬁcient cleavage of both REBOV- and CIEBOV-GP.
Thus, hepsin and TMPRSS2 might activate REBOV- and/or CIEBOV-
GP for host cell entry. However, coexpression of neither protease in
virus producing cells (Fig. 5A) or in viral target cells (Fig. 5B) allowed
efﬁcient GP-driven entry into cells pretreated with a cathepsin B/L in-
hibitor, while TMPRSS2 was able to partially rescue blockade of SARS-
S-driven infection (Fig. 5C), as expected (Glowacka et al., 2011;
Matsuyama et al., 2010; Shulla et al., 2011). These results suggest
that TMPRSS2 and hepsin cannot functionally replace cathepsin B/L
activity in EBOV target cells.
Cathepsin B/L activity is essential for efﬁcient Ebola but not Marburg
virus glycoprotein-driven entry into macrophages
Previous studies on the role of cathepsins in the proteolytic activa-
tion of EBOV-GP largely focused on cell lines (Chandran et al., 2005;
Schornberg et al., 2006), while the importance of these enzymes for
viral entry into macrophages, a key target cell in ﬁlovirus infection,
has not been examined. Incubation of macrophages with CA074Meand leupeptin inhibited entry driven by ZEBOV- and REBOV-GP but
not VSV-G (Fig. 6). In contrast, only leupeptin but not CA074Me efﬁ-
ciently reduced MARV-GP-dependent infection (Fig. 6) and AEBSF
had no effect (data not shown), indicating that MARV might employ
other cellular proteases in addition to or instead of cathepsins B and
L for entry into macrophages.
Discussion
Many viruses which cause disease in humans, including HIV, inﬂu-
enza virus, and SARS-CoV, acquire infectivity only upon proteolytic ac-
tivation of their glycoproteins (Bertram et al., 2010b; Harrison, 2008).
Whether the same holds true for EBOV has long been unclear, since
cleavage at a furin consensus site in EBOV-GP was found to be dispens-
able for infectivity (Neumann et al., 2002, 2007). Recent ﬁndings dem-
onstrated that the endo-/lysosomal cysteine proteases cathepsin L and
particularly cathepsin B can activate ZEBOV-GP (Chandran et al., 2005;
26
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7K. Gnirß et al. / Virology 424 (2012) 3–10Schornberg et al., 2006), indicating that proteolytic activation of EBOV
occurs upon viral uptake into host cells. Interestingly, proteolysis of
GP by cathepsins B/L seems to be required for engagement of the endo-
somalmembrane proteinNiemann–Pick C1,which is essential for infec-
tious ﬁlovirus entry (Carette et al., 2011; Cote et al., 2011). Here, we
show that the GPs of all EBOV subspecies depend on cathepsin B/L activ-
ity for viral entry into 293T cells, although to different degrees. Similar-
ly, EBOV-GP-driven infection of macrophages required cathepsin B/L
activity. In contrast, MARV-GP-driven entry was largely cathepsin B/L-
independent andwas promoted by so far uncharacterized host cell pro-
teases. Finally, TMPRSS2 and hepsin, members of the TTSP family
known to activate SARS-CoV and inﬂuenza viruses (Böttcher et al.,
2006; Glowacka et al., 2011; Matsuyama et al., 2010; Shulla et al.,
2011), were able to cleave EBOV-GP but were unable to support GP-
dependent, cathepsin B/L-independent host cell entry.
Previous studies reported that the GPs of the four EBOV subspecies
differ in their interactions with host cells; for instance, ZEBOV- but
not REBOV-GP was found to interact efﬁciently with the dendritic
cell lectin hMGL (Takada et al., 2004) and expression of ZEBOV-GP
but not REBOV was shown to interfere with the integrity of the
blood vessel endothelium (Yang et al., 2000). Our results demonstrate
that the GPs of all four EBOV species depend on cathepsin B/L-activity
for host cell entry. Sensitivity of ZEBOV-GP to inhibition by CA074Me
was highest of all GPs tested, suggesting that ZEBOV-GPmight be par-
ticularly dependent on activation by cathepsins B/L. It needs to be
noted that CA074Me was more than 200-fold more active against ca-
thepsin B compared to cathepsin L at the highest concentration used
(4 μM), and the inhibitory effects observed in infection experiments
might thus mainly stem from cathepsin B blockade. The dependence
on the individual activities of cathepsin B and cathepsin L might
vary between ZEBOV- and REBOV-GP, with the latter being insensi-
tive to inhibition by CA074 but sensitive to blockade by cathepsin L
inhibitor III. The reasons for these differences are at present un-
known, but might relate to differences in the cathepsin B/L target
sites. Cathepsin L cleavage sites in ZEBOV-GP have recently been pro-
posed (Hood et al., 2010) and their sequences indeed differ between
ZEBOV- and REBOV-GP. Moreover, Wong and colleagues selected
EBOV-GP variants with amino acid changes, which allow entry into
cells treated with a cathepsin B inhibitor, and some of the respective
amino acids are not conserved between EBOV species (Wong et al.,
2010). Alternatively, some GPs might be intrinsically more amenable
to proteolysis than others and might thus exhibit a different require-
ment for cathepsin activity.Entry of MARV-GP-bearing viruses into 293T cells and macro-
phages was largely resistant to the cathepsin B/L inhibitor
CA074Me. These results are in agreement with a previous study
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8 K. Gnirß et al. / Virology 424 (2012) 3–10showing that inhibition of cathepsin B/L efﬁciently blocked ZEBOV
but not MARV entry into Vero E6 cells, although inhibition of viral
replication was observed (Sanchez, 2007). In contrast, Huang and col-
leagues reported that engineered expression of cathepsin L in murine
cathepsin L knock-out cells increased MARV-GP-mediated entry
(Huang et al., 2006). The reasons for these discrepant results are at
present unclear. Our observations suggest that MARV does either
not require proteolytic activation of its GP for entry or that MARV
and EBOV rely on different host cell proteases to ensure their activa-
tion. The ﬁnding that leupeptin, an inhibitor of cysteine and serine
proteases, blocked MARV-GP-driven entry indicates that the latter is
the case, but the responsible protease(s) remain(s) to be deﬁned.
Many TTSPs play an important role in cancer development (Choi
et al., 2009). Recent studies demonstrate that several of these pro-
teins might also promote viral infections by facilitating activation of
viral glycoproteins. Thus, TMPRSS2 was shown to activate inﬂuenzavirus (Böttcher et al., 2006), human metapneumovirus (Shirogane
et al., 2008) and SARS-CoV (Glowacka et al., 2011; Matsuyama et al.,
2010; Shulla et al., 2011). The latter ﬁnding is remarkable, because
it has previously been reported that SARS-CoV relies on cathepsins
B and L for its activation (Simmons et al., 2005). The observation
that cathepsin B/L-dependence is abrogated by TMPRSS2 suggests
that virions are activated by TMPRSS2 during contact with the plasma
membrane of target cells and then reach endo-/lysosomes, which
contain cathepsins B and L, in an already activated from. Our results
show that TMPRSS2 and the related protease hepsin can cleave
REBOV- and/or CIEBOV-GP, potentially at the same site as furin.
ZEBOV-GP and SEBOV-GP are presumably also cleaved by TMPRSS2
but cleavage could not be demonstrated because of the efﬁcient pro-
cessing of these proteins by endogenous furin in 293T cells (Wool-
Lewis and Bates, 1999). However, cleavage by TMPRSS2 and hepsin
did not result in GP activation and cathepsin B/L-independent cellular
entry, in agreement with previous ﬁndings indicating that the furin
cleavage site is dispensable for viral spread and pathogenicity
(Neumann et al., 2002, 2007). Thus, unlike the situation noted for
SARS-CoV, TTSPs are unlikely to rescue EBOV from the antiviral effect
of therapeutically applied cathepsin B/L-inhibitors.
Macrophages are key targets of EBOV in experimentally infected
animals and humans and infection is believed to result in the uncon-
trolled release of cytokines, a hallmark of EBOV disease (Feldmann
and Geisbert, 2011; Hartman et al., 2010). ZEBOV- and REBOV-GP-
driven entry into macrophages was dependent on cathepsin B/L ac-
tivity. These results suggest that cathepsin B/L inhibitors could dis-
play antiviral activity in EBOV infected individuals. However, a
recent study suggested that ZEBOV-GP-driven entry into dendritic
cells, which are targets of ZEBOV (Geisbert et al., 2003; Mahanty et
al., 2003), requires cathepsin B but not L activity (Martinez et al.,
2010). These ﬁndings, combined with the present observation that
blockade of EBOV-GP-dependent entry by cathepsin inhibitors is fre-
quently incomplete suggest that efﬁcacy of inhibitors needs to be im-
proved compared to presently available compounds in order to
achieve a profound antiviral effect and such efforts are ongoing
(Shah et al., 2010). In sum, cathepsins B and L are required for efﬁ-
cient EBOV- but not MARV-GP-driven infection of cell lines and
macrophages.
Materials and methods
Cell culture
293T cells were maintained in DMEM (Gibco) supplemented with
10% fetal bovine serum (FBS; Biochrom) and 1% penicillin/streptomy-
cin. 293T-ACE2 (293T-232 cells, (Glowacka et al., 2010)) cells were
cultured similar to 293T with additional 0.1% Zeocin (Invitrogen). Pri-
mary human monocyte-derived macrophages were cultured in
monocyte differentiation medium (X-VIVO 10 medium (Lonza) sup-
plemented with 1% human ﬁbrin-depleted plasma and 1% penicillin/
streptomycin). All cells were grown in a humidiﬁed atmosphere at
37 °C and 5% CO2.
Generation of primary human monocyte-derived macrophages
For primary human monocyte-derived macrophage preparation,
the buffy coat of thrombocyte-depleted blood was collected upon
Ficoll density gradient centrifugation. Buffy coats were washed
three times by resuspension in ice-cold PBS and centrifugation at
2000, 1500 and 1200 rpm. Cells were resuspended in 40 ml monocyte
adhesionmedium (RPMI 1640 (PAA) supplemented with 7.5% human
ﬁbrin-depleted plasma and 1% penicillin/streptomycin) and seeded in
two 15-cm tissue-culture dishes. After 45–90 min incubation non-
adherent cells were removed by washing the cells seven times with
20 ml 37 °C warm PBS. The adherent cells were incubated in 20 ml
9K. Gnirß et al. / Virology 424 (2012) 3–10monocyte adhesion medium overnight. The next day, the cells were
washed with PBS, detached with StemPro Accutase (Invitrogen) and
seeded into 96-well plates. Monocytes were differentiated into mac-
rophages by culture in monocyte differentiation medium for seven
days.
Plasmids
Expression plasmids encoding the glycoproteins of the EBOV spe-
cies Zaire ebolavirus, Sudan ebolavirus, Cote d'Ivoire ebolavirus and Res-
ton ebolavirus with or without a C-terminal V5-tag as well as MARV,
SARS-coronavirus and vesicular stomatitis virus (VSV) were de-
scribed previously (Hofmann et al., 2004; Kühl et al., 2011a, 2011b;
Marzi et al., 2006). Expression plasmids for proteases TMPRSS2 and
hepsin were also described previously (Bertram et al., 2010a;
Chaipan et al., 2009; Shirogane et al., 2008). For generation of
human immunodeﬁciency virus (HIV) pseudotypes, plasmid pNL4-3
E–R–Luc was employed (Connor et al., 1995).
Western blotting
For detection of TMPRSS2- and hepsin-mediated cleavage of
EBOV-GP, 293T cells seeded in 6-well plates were cotransfected
with 5 μg of EBOV-GP and 1 μg protease expression plasmids employ-
ing calcium phosphate and transfection medium was replaced by
fresh culture medium at 8 h post transfection. Cells were lysed at
48 h post transfection, proteins were separated by SDS-PAGE and
transferred onto nitrocellulose membranes. The V5-tag was detected
by using a mouse anti-V5 antibody (Invitrogen). As loading control,
β-actin was detected employing a mouse monoclonal antibody
(Sigma).
Production of pseudotypes
For generation of HIV-1 NL4-3-based pseudotypes carrying the
different EBOV-GPs, SARS-S, VSV-G or no glycoprotein as control,
cells were calcium phosphate-cotransfected with 12 μg DNA at a 1:1
ratio of pNL4-3 E–R–Luc and glycoprotein expression plasmid or
empty plasmid in T25 tissue culture ﬂasks. In some experiments, ad-
ditionally 0.25 μg protease expression plasmids were cotransfected.
Medium was changed at 16 h post transfection. At 48 h post transfec-
tion, supernatants were harvested, passed through 0.45 μm pore-size
ﬁlters and concentrated using VivaSpin columns (Sartorius). Virus
stocks were either normalized for equal p24-content by ELISA (Ad-
vanced Bioscience Laboratories) or comparable infectivity for 293T
cells by luciferase assay (Promega).
Infection assay
For infection experiments, 293T cells or 293T-ACE2 cells were
seeded in 96-well plates at a density of 5×104 cells/well. Monocytes
were seeded and differentiated in 96-well plates at a density of
7.5×104 cells/well, and infected the latest at day 10 after addition
of differentiation medium. Cells were infected with 50 μl of p24-
antigen- or infectivity-normalized virus. 293T cells and macrophages
were infected by spin-oculation (O'Doherty et al., 2000) at 2000 rpm
and 4 °C for 2 h. Medium was exchanged 8 h post infection and infec-
tivity was measured by determining luciferase activity in cell lysates
at 72 h post infection using a commercially available kit (Promega).
Determination of protease inhibitor activity and speciﬁcity
For determination of inhibitor speciﬁcity, 293T cells were seeded
and treated with protease inhibitors as described below for infection
experiments. After 8 h cells were washed with PBS and lysed. Cathep-
sin B, L (Merck) and S (AnaSpec) activity in cell lysates was measuredusing commercially available kits according to the manufacturer's
instructions.
Protease inhibitor experiments
Protease inhibitors CA074Me (Calbiochem), AEBSF (Roth), cathep-
sin L inhibitor III (Merck), MDL28170, E64c or leupeptin (Sigma)
were diluted in PBS and used in the indicated concentrations. For pro-
tease inhibition, target cells were pretreated with the indicated inhib-
itors for 60 min and infected with infectivity-normalized pseudotypes
in the presence of inhibitor. The inhibitor containing medium was
replaced by fresh culture medium without inhibitor at 8 h post
infection.
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